| 普乐沙福用于动员自体外周血造血干细胞的中国专家共识(2021版) |
| |
| 引用本文： | 中国抗癌协会血液肿瘤专业委员会. 普乐沙福用于动员自体外周血造血干细胞的中国专家共识(2021版)[J]. 中国肿瘤临床, 2021, 48(9): 433-439. DOI: 10.3969/j.issn.1000-8179.2021.09.184 |
| |
| 作者姓名： | 中国抗癌协会血液肿瘤专业委员会 |
| |
| 摘 要： | 普乐沙福是一种CXC趋化因子受体4(CXC chemokine receptor 4,CXCR4)拮抗剂,可动员造血干细胞自骨髓释放至外周血中.普乐沙福分别于2018年12月和2020年8月获国家药品监督管理局(NMPA)批准用于非霍奇金淋巴瘤(non-Hodgkin's lym-phoma,NHL)和多发性骨髓瘤(m...
|
| 关 键 词： | 自体外周血干细胞动员 普乐沙福 中国专家共识 |
| 收稿时间： | 2021-01-27 |
The Chinese expert consensus on plerixafor in mobilizing autologous peripheral blood stem cells (2021 edition) |
| |
| Abstract: | Plerixafor is a CXC chemokine receptor 4 (CXCR4) antagonist that mobilizes hematopoietic stem cells from the bone marrow to the peripheral blood. Plerixafor was approved by the National Medical Products Administration (NMPA) to mobilize autologous hematopoietic stem cells in patients with non-Hodgkin's lymphoma (LNHL) in December 2018 and in patients with multiple myeloma in August 2020. So far, although plerixafor has been marketed abroad for more than 10 years and has been widely used in clinical practice, there is no relevant consensus regarding its standard clinical application in China because of its short marketing time in China and little clinical practice experience. This article summarizes relevant research data on plerixafor and establishes Chinese expert consensus to provide a reference for clinicians. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
